Vectura

Vectura Group Plc is a UK-based company specializing in the development of inhaled drug delivery products. Here’s a comprehensive overview of the company:

Mission and Vision

Vectura aims to enhance patient care through innovative inhalation therapies. The company focuses on developing specialized inhaled products for chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

Key Products and Services

Vectura is known for its expertise in:

• Dry Powder Inhalers (DPI): Devices designed for delivering medication directly to the lungs.

• Metered Dose Inhalers (MDI): Pressurized devices that deliver specific amounts of medication.

• Nebulizers: Devices that convert liquid medication into mist for inhalation.

The company offers a range of services including:

• Formulation development

• Pharmaceutical analysis

• Device platforms

• Process development and technical transfer

• Product manufacturing and regulatory services

Partnerships and Collaborations

Vectura has established partnerships with major pharmaceutical companies such as GlaxoSmithKline, Novartis, and Mundipharma to develop and market inhaled medicines. The company has successfully contributed to the launch of 13 inhaled medicines that have generated over $11 billion in sales since their introduction.

Recent Developments

1. Acquisition by Philip Morris International (PMI):

• In September 2021, Vectura was acquired by PMI for approximately £1.1 billion. This acquisition was part of PMI's strategy to diversify into non-nicotine products.

2. Sale to Phillips Medisize:

• In May 2024, PMI sold Vectura to Phillips Medisize, which is owned by Molex Asia Holdings Ltd. This sale was attributed to "unwarranted opposition" to PMI's transformation strategy.

3. Formation of Vectura Fertin Pharma:

• Following the acquisition of Fertin Pharma, Vectura was integrated into a new entity called Vectura Fertin Pharma in March 2022, focusing on both inhalation and oral delivery systems.

Financial Performance

Vectura has demonstrated significant financial success through its partnerships and product launches. The inhaled products developed with Vectura's technology have been used by approximately 10 million patients worldwide as of 2020.

Conclusion

Vectura Group Plc stands out as a leading player in the inhalation drug delivery market with over 20 years of experience. Its focus on innovative inhalation therapies positions it well within the pharmaceutical industry, particularly as it continues to expand its portfolio through strategic partnerships and acquisitions. The recent transitions in ownership highlight Vectura's adaptability and commitment to enhancing patient care through advanced drug delivery systems.